References
1. Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis. 2006;24(1-2):11-46. doi:10.1159/000091298
2. Tennant SM, Hartland EL, Phumoonna T, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008;76(2):639-645. doi:10.1128/IAI.01138-07
3. Yang ZY, Huang Y, Ganesh L, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004;78(11):5642-5650. doi:10.1128/JVI.78.11.5642-5650.2004
4. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11-12):1269-1281. doi:10.1111/j.1365-2036.2011.04874.x
5. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047-2057. doi:10.1111/j.1572-0241.2007.01275.x
6. Zhu, N., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382, 727-733 (2020).
7. Wu, Z. & McGoogan, J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA (2020).
8. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831-1833.e3. doi:10.1053/j.gastro.2020.02.055
9. Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-
2 infection. Gut 2020;69:997–1001.
10. Zhang H, Kang Z, Gong H, et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut
2020;69:1010–8.
11. American Journal of Gastroenterology. Increase Risk of COVID-19 Among Users of Proton Pump Inhibitors. https://journals.lww.com/ajg/Documents/AJG-20-1811_R1(PUBLISH%20AS%20WEBPART).pdf. Accessed August 01, 2020.
12. Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut Published Online First: 30 July 2020. doi: 10.1136/gutjnl-2020-322248
13. Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams
JA, on behalf of the Famotidine Research Group Famotidine Research Group, Sobieszczyk ME,
Markowitz DD, Gupta A, O’Donnell MR, Li J, Tuveson DA, Jin Z, Turner WC, Landry DW, Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study, Gastroenterology (2020), doi: https://doi.org/10.1053/j.gastro.2020.05.053.
14. Janowitz T, Gablenz E, Pattinson D, et al. Gut Epub ahead of print: [01 August 2020]. doi:10.1136/gutjnl-2020-321852
15. Vilcu A, Sabatte L, Blanchon T, et al. Association Between Acute Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses. JAMA Netw Open. 2019;2(11):e1916205. doi:10.1001/jamanetworkopen.2019.16205
16. Sarkar M, Hennessy S, Yang Y-X. Proton-Pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008;149:391–8.
17. Laheij RJF, Sturkenboom MCJM, Hassing R-J, et al. risk of community-acquired
pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955–60.
18. Wang C-H, Li C-H, Hsieh R, et al. Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomised controlled trials and observational studies. Expert Opin Drug Saf 2019;18:163–72.
19. Darnell ME, Subbarao K, Feinstone SM, et al. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods 2004;121:85-91.
20. Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020.
21. Bourinbaiar AS, Fruhstorfer EC. The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: Identification of a new class of antiviral agents. Life Sci. 1996;59(23):365–370
22. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;. https://doi.org/10.1016/j.
apsb.2020.02.008.
23. Clinical Trials. Multi-site Adaptive Trials for COVID-19. https://clinicaltrials.gov/ct2/show/NCT04370262. Accessed August 01, 2020.
24. Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily–a randomised, two-way crossover study. Aliment Pharmacol Ther 2005;21:963-7.
25. Johnson DA, Stacy T, Ryan M, et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005;22:129-34.
26. Katz PO, Castell DO, Chen Y, et al. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomised, three-way crossover study. Aliment Pharmacol Ther 2004;20:399-406.